Center for Drug Evalutaion and Research

Orexigen Therapeutics (NASDAQ: OREX) was upgraded from Neutral to Overweight with a $10 price target by J.P. Morgan on Thursday following FDA approval of the drug Belviq (lorcaserin). Arena Pharmaceuticals (NASDAQ: ARNA) scored a big hit this week after this decision to approve the obesity drug...